05 June 2020 | News
WHO Director-General Tedros Adhanom Ghebreyesus confirmed after safety data were reviewed by the Data Safety and Monitoring Committee of the Solidarity Trial
image courtesy: freepik
The Executive Group of the Solidarity Trial decided on 23 May 2020 to implement a temporary pause of the hydroxychloroquine arm of the trial, because of concerns raised about the safety of the drug. This decision was taken as a precaution while the safety data were reviewed by the Data Safety and Monitoring Committee of the Solidarity Trial.
A WHO report on 25 May suggested that "As per the initial trial protocol, chloroquine and hydroxychloroquine had both been selected as potential drugs to be tested within the Solidarity Trial. However the trial was only ever pursued with hydroxychloroquine, so chloroquine was removed from this page as a listed treatment option understudy"